all report title image
  • Published In : Mar 2024
  • Code : CMI6750
  • Pages : 164
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

The Lenalidomide Drug Market is estimated to be valued at USD 13.21 Bn in 2024 and is expected to reach USD 20.45 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Lenalidomideis an immunomodulatory drug used for the treatment of multiple myeloma and myelodysplastic syndromes. It works by modulating the immune system and inhibiting angiogenesis. Lenalidomide was first approved by the U.S. Food and Drug Administration in 2006 and since then has become a core drug in the treatment regimen for multiple myeloma. It is commonly used in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Lenalidomide continues to have a strong market position due to its efficacy and increasingly long duration of treatment as new lines of therapy emerge.

Market Dynamics:

The global Lenalidomide drug market growth is driven by the rising prevalence of multiple myeloma globally. According to 2024 estimates of American Cancer Society, a non-profit organization dedicated to eliminating cancer, in the U.S., approximately 35,780 new cases of myeloma will be diagnosed (19,520 in men and 16,260 in women), with an estimated 12,540 deaths (7,020 in males and 5,520 in women). An aging population and improved diagnosis and awareness are contributing to the increasing disease prevalence. Furthermore, the market has witnessed restraints from patent expirations of branded drugs and the introduction of generic competition. However, the key players are focusing on the expansion of Lenalidomide's indications to broader patient segments and line of therapies, which is opening new avenues of growth. Additionally, increasing research on drug combinations and next-gen treatments presents opportunities for market players to strengthen their market position.

Key Features of the Study:

  • This report provides an in-depth analysis of the global Lenalidomide drug market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Lenalidomide drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Cipla Inc., Apotex Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lotus, NATCO Pharma Limited, Sandoz Group AG, Aurobindo Pharma, Zydus Group, and Intas Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Lenalidomide drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Lenalidomide drug market.

Detailed Segmentation:

  • Strength:
    • 10 mg
    • 20 mg
    • 25 mg
    • Others
  • Application:
    • Multiple myeloma (MM)
    • Transfusion-dependent anemia
    • Mantle cell lymphoma (MCL)
    • Others
  • Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region: 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • Reddy’s Laboratories Ltd. 
    • Cipla Inc. 
    • Apotex Inc.
    • Viatris Inc. 
    • Sun Pharmaceutical Industries Ltd.  
    • Lotus
    • NATCO Pharma Limited
    • Sandoz Group AG
    • Aurobindo Pharma
    • Zydus Group
    • Intas Pharmaceuticals Ltd.

Detailed Segmentation:

  • Strength:
    • 10 mg
    • 20 mg
    • 25 mg
    • Others
  • Application:
    • Multiple myeloma (MM)
    • Transfusion-dependent anemia
    • Mantle cell lymphoma (MCL)
    • Others
  • Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region: 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo